Guidelines for WELIREG® (belzutifan)
Belzutifan (WELIREG) is a recommended option by National Comprehensive Cancer Network® (NCCN®) across 2 VHL disease–associated tumor types1,2
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)
for Kidney Cancer (confirmed hereditary VHL disease–associated RCC)
NCCN Guidelines® for Kidney Cancer (confirmed hereditary VHL disease–associated RCC)
Belzutifan (WELIREG) is the only preferred systemic therapy option (NCCN category 2A) for
patients with VHL disease–associated RCC not requiring immediate surgery.1
Belzutifan (WELIREG) is the only preferred systemic therapy option (category 2A) for patients with VHL disease–associated RCC not requiring immediate surgery.1
NCCN Guidelines® for CNS Cancers
(VHL disease–associated CNS hemangioblastomas)
NCCN Guidelines for CNS Cancers (VHL disease–associated CNS hemangioblastomas)
Belzutifan (WELIREG) is the only systemic therapy option identified as useful in certain
circumstances (NCCN category 2A) for patients with VHL disease–associated CNS hemangioblastomas not requiring immediate surgery or for those whom surgery is
contraindicated due to location, prior surgeries, or comorbidities, growing or symptomatic.2
Belzutifan (WELIREG) is the only systemic therapy option identified as useful in certain circumstances (NCCN category 2A) for patients with VHL disease–associated CNS hemangioblastomas not requiring immediate surgery or for those whom surgery is contraindicated due to location, prior surgeries, or comorbidities, growing or symptomatic.2
WELIREG is indicated for the treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery.